SLC2A1 and type 2 diabetes mellitus: Despite these results, phloridzin was abandoned as a potential treatment of type 2 diabetes due to its rapid degradation and poor absorption in the gastrointestinal tract, where it is hydrolysed into glucose and phloretin, which in turn inhibit facilitative glucose transporters, such as GLUT-1 [5], the main glucose transporter in non-insulin-dependent tissues.